What the trial was testing
The SYMPATICO enrolled 366 patients with mantle cell lymphoma. The study was sponsored by Pharmacyclics LLC and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
31.9 vs. 22.1 months — how long the cancer stayed under control on the combination vs. ibrutinib alone.
The Lancet Oncology · 2025 · NCT03112174
These findings — that median time before relapsed mantle cell lymphoma progressed on ibrutinib + venetoclax vs. ibrutinib alone — were published in the The Lancet Oncology and represent the headline result of the study.
Researchers tracked outcomes across 366 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with mantle cell lymphoma, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Both ibrutinib (Imbruvica) and venetoclax (Venclexta) are FDA-approved for B-cell cancers individually, and the combination is becoming an option in trials and care for relapsed mantle cell lymphoma. SYMPATICO shows that doubling up on targeted oral pills meaningfully extends time before the cancer regrows after first-line therapy. Ask your oncologist whether you'd be a candidate.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open mantle cell lymphoma trials
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts
Auto Stem Cell Transplant for Lymphoma Patients
This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.